Evelo Biosciences, Inc. (EVLO)

0.0495 +0.0020 (+4.21%) 收市：02:32PM EDT

Evelo Biosciences, Inc.

620 Memorial Drive
5th Floor
Cambridge, MA 02139
United States
617 577 0300
https://www.evelobio.com

版塊: Healthcare
行業: Biotechnology
全職員工: 66

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Craig R. Jalbert CIRA	President, Secretary, Principal Executive, Financial and Accounting Officer & Director	無	無	1962
Dr. Chun Zhang Ph.D.	Chief Technical Operations & Quality Officer	無	無	無
Dr. Mark Bodmer Ph.D.	Chief Scientific Officer and President of Research & Development	668.8k	無	1958
Ms. Jessica Cotrone	VP & Head of Communications	無	無	無
Ms. Leslie Wardwell-Scott Ph.D.	VP and Head of Corporate Development & Strategic Integration	無	無	無
Dr. Andrea Itano Ph.D.	Head of Research	無	無	無
Dr. Duncan McHale M.D., MBBS, Ph.D.	Chief Medical Officer	661.97k	無	1967
Mr. Douglas Maslin	Senior Director & Immunology Clinical Lead	無	無	無

截止 2017年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

公司管治

截至 無 止，Evelo Biosciences, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。